Advancements in Disease Modeling and Drug Discovery Using iPSC-Derived Hepatocyte-like Cells
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Serving as the metabolic hub of the human body, the liver is a vital organ that performs a variety of important physiological functions. Although known for its regenerative potential, it remains vulnerable to a variety of diseases. Despite decades of research, liver disease remains a leading cause of mortality in the United States with a multibillion-dollar-per-year economic burden. Prior research with model systems, such as primary hepatocytes and murine models, has provided many important discoveries. However, progress has been impaired by numerous obstacles associated with these models. In recent years, induced pluripotent stem cell (iPSC)-based systems have emerged as advantageous platforms for studying liver disease. Benefits, including preserved differentiation and physiological function, amenability to genetic manipulation via tools such as CRISPR/Cas9, and availability for high-throughput screening, make these systems increasingly attractive for both mechanistic studies of disease and the identification of novel therapeutics. Although limitations exist, recent studies have made progress in ameliorating these issues. In this review, we discuss recent advancements in iPSC-based models of liver disease, including improvements in model system construction as well as the use of high-throughput screens for genetic studies and drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Self-citationRobust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice
Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M. A., Finegold, M., & Grompe, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1326 · Cited by 835
Generation of Functional Human Hepatic Endoderm From Human Induced Pluripotent Stem Cells
Sullivan, G. J., Hay, D. C., Park, I.-H., Fletcher, J., Hannoun, Z., Payne, C. M., Dalgetty, D., Black, J. R., Ross, J. A., Samuel, K., et al. (2010) · Hepatology · doi:10.1002/hep.23335 · Cited by 445
High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell–Derived Organoids
Shinozawa, T., Kimura, M., Cai, Y., Saiki, N., Yoneyama, Y., Ouchi, R., Koike, H., Maezawa, M., Zhang, R.-R., Dunn, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.002 · Cited by 378
Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease
Ramli, M. N. B., Lim, Y. S., Koe, C. T., Demircioglu, D., Tng, W., Gonzales, K. A. U., Tan, C. P., Szczerbinska, I., Liang, H., Soe, E. L., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.010 · Cited by 278
Identification of small molecules for human hepatocyte expansion and iPS differentiation
Shan, J., Schwartz, R. E., Ross, N. T., Logan, D. J., Thomas, D., Duncan, S. A., North, T. E., Goessling, W., Carpenter, A. E., & Bhatia, S. N. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1270 · Cited by 254
Self-citationHuman hepatic organoids for the analysis of human genetic diseases
Guan, Y., Xu, D., Garfin, P. M., Ehmer, U., Hurwitz, M., Enns, G., Michie, S., Wu, M., Zheng, M., Nishimura, T., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.94954 · Cited by 243 · cited 1×
“Alagille Syndrome 3D organoids containing hepatocytes and cholangiocytes Impaired bile duct formation and regenerative capacity [71]”
BackgroundSmall-Molecule-Driven Hepatocyte Differentiation of Human Pluripotent Stem Cells
Siller, R., Greenhough, S., Naumovska, E., & Sullivan, G. J. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.04.001 · Cited by 203
Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
Warren, C. R., O’Sullivan, J. F., Friesen, M., Becker, C. E., Zhang, X., Liu, P., Wakabayashi, Y., Morningstar, J. E., Shi, X., Choi, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.01.010 · Cited by 191
Cited by
Replacing Animal Testing with Stem Cell-Organoids : Advantages and Limitations
Park, G., Rim, Y. A., Sohn, Y., Nam, Y., & Ju, J. H. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10723-5 · Cited by 92
Guo, K., & van den Beucken, T. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01317-2 · Cited by 28
Inui, J., Ueyama-Toba, Y., Imamura, C., Nagai, W., Asano, R., & Mizuguchi, H. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123148 · Cited by 5
Cryopreservation of Hepatocyte Organoid-Derived Cells Generated from Human iPS Cells
Nagai, W., Inui, J., Ueyama-Toba, Y., Asano, R., & Mizuguchi, H. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00276 · Cited by 1
Ghanem, S. S., Al-Barazenji, T., Badi, R., & Abdelalim, E. M. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12480-9
Metadata
- Authors
- Blaszkiewicz, J., & Duncan, S. A.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2022-03-24
- Volume
- 13
- Issue
- 4
- Pages
- 573
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W4220891262
- Cited by
- 27
- References
- 13
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advancements in Disease Modeling and Drug Discovery Using iPSC-Derived Hepatocyte-like Cells. https://app.cochat.ai/papers/10.3390/genes13040573
- The paper
- Blaszkiewicz, J., & Duncan, S. A. (2022). Advancements in Disease Modeling and Drug Discovery Using iPSC-Derived Hepatocyte-like Cells. Genes. https://doi.org/10.3390/genes13040573
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.